Abstract

Maintaining high cure rates while lowering early and late treatment-related toxicity remains a challenge for patients with advanced-stage Hodgkin

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call